Alnylam Pharma (ALNY) AI Stock Analysis

• Market Cap: $40.57B
• Dividend Yield: N/A
• Average Volume (3M): 818.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: 17.21%
• EPS Growth: 21.16%
• Country: US
• Employees: 2,230
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 130,388,400
• 10 Day Avg. Volume: 783,419
• 30 Day Avg. Volume: 818,394
• PEG Ratio: -40.65
• Price to Book (P/B): 350.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -539.05
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 4.52
• Enterprise Value/Gross Profit: 20.23
• Enterprise Value/Ebitda: -120.81
• 1Y Price Target: $344.77
• Price Target Upside: 6.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23

• Rating: 66 Neutral
• Price Target: $337.00 ▲(4.40%Upside)

Alnylam Pharma's overall score reflects a promising growth trajectory with strong technical indicators and strategic corporate actions. However, the high financial leverage and negative earnings impact the valuation, while the positive earnings call sentiment and corporate event developments highlight potential for future improvement.

Positive Factors

Market Opportunity

There is a convincing multi-billion dollar opportunity for Amvuttra in TTR amyloidosis, supported by strong uptake in newly diagnosed patients and those progressing on prior therapies.

Market Share and Growth

The survey indicates that Amvuttra could achieve a 29% market share at its peak, suggesting faster uptake than currently estimated, which could represent an upside to estimates.

Performance Outlook

Raising the Alnylam price target to $348 after increasing Amvuttra estimates indicates a positive outlook for the company's future performance.

Negative Factors

Revenue Projections

Building momentum in TTR and beyond: execution, innovation, and a leading biotech platform poised to generate annual revenues of more than $10 billion.

Sales Forecast

In the less conservative scenario, 1H25 TTR sales could deliver ~50%-55% of the midpoint of 2025 TTR guidance, suggesting clear upside.

Alnylam Pharma Business Overview & Revenue Model

Company Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). The company operates in the healthcare sector and specializes in the development of therapies for genetically defined diseases. Alnylam's core products are RNAi-based medicines designed to treat a variety of conditions, including rare genetic diseases, cardio-metabolic diseases, and infectious diseases.

How the Company Makes Money

Alnylam Pharmaceuticals generates revenue primarily through the sale of its RNAi-based therapeutic products. The company earns money from product sales, particularly from its commercialized medicines such as ONPATTRO, GIVLAARI, and OXLUMO, which target specific genetic disorders. In addition to product sales, Alnylam also engages in strategic collaborations and partnerships with other pharmaceutical companies, which provide additional revenue streams through milestone payments, licensing fees, and royalties. These partnerships often involve the joint development and commercialization of RNAi therapeutics, leveraging Alnylam's technology platform and expertise in RNA interference.

Alnylam Pharma Financial Statement Overview

Summary

Alnylam Pharma shows promising revenue growth but struggles with profitability and operational efficiency. Despite strong gross profit margins, negative EBIT and EBITDA margins highlight ongoing challenges. The high leverage poses financial risk, but strong liquidity from cash reserves provides stability. Cash flow challenges persist, with positive financing activities offering some relief.

Income Statement

The income statement reveals a mixed performance for Alnylam Pharma. Despite a substantial revenue growth from $1.03 billion in 2022 to $2.35 billion TTM, the company continues to operate at a net loss, with a net profit margin of -11.49% TTM. Gross profit margin remains strong at 89.04% TTM, indicating efficient cost management. However, negative EBIT and EBITDA margins of -4.91% and -6.22% respectively, highlight ongoing operational challenges. While revenue growth is promising, the lack of profitability is a concern.

Balance Sheet

Alnylam Pharma's balance sheet shows a high level of debt relative to equity, with a debt-to-equity ratio of 11.27 TTM, indicating significant leverage. The return on equity (ROE) remains negative due to ongoing losses. However, the equity ratio is 2.74% TTM, which is positive but still reflects a weak equity position. The company's high level of cash and short-term investments is a positive aspect, providing liquidity support.

Cash Flow

The cash flow statement highlights some positive trends, with a significant financing cash flow of $309.33 million TTM, bolstering liquidity. However, both operating cash flow and free cash flow remain negative, indicating ongoing cash burn from operations and capital expenditures. The operating cash flow to net income ratio is negative, further emphasizing cash flow challenges despite a minor improvement in free cash flow growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.25B	1.83B	1.04B	844.29M	492.85M
Gross Profit	1.92B	1.52B	868.60M	704.14M	414.80M
EBITDA	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
Net Income	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Balance Sheet
Total Assets	4.30B	3.83B	3.55B	3.64B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.69B	2.44B	2.19B	2.44B	1.87B
Total Debt	1.30B	2.68B	1.32B	997.59M	521.19M
Total Liabilities	4.17B	4.05B	3.70B	3.06B	2.39B
Stockholders Equity	67.09M	-220.64M	-158.22M	588.20M	1.02B
Cash Flow
Free Cash Flow	-42.59M	41.95M	-613.33M	-718.07M	-685.32M
Operating Cash Flow	-8.31M	104.16M	-541.27M	-641.69M	-614.96M
Investing Cash Flow	-116.84M	-336.35M	169.35M	-273.30M	-435.52M
Financing Cash Flow	294.16M	172.13M	425.75M	1.25B	994.98M

Alnylam Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 322.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Positive. The current price of 322.81 is above the 20-day moving average (MA) of 320.37, above the 50-day MA of 302.48, and above the 200-day MA of 269.08, indicating a bullish trend. The MACD of 4.95 indicates Positive momentum. The RSI at 58.45 is Neutral, neither overbought nor oversold. The STOCH value of 45.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALNY.

Alnylam Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPRX	78 Outperform	$20.53B	14.89	16.57%	2.47%	1.15%	37.75%
UTHR	76 Outperform	$13.23B	11.90	19.94%	―	19.85%	21.16%
ARGX	76 Outperform	$34.23B	41.61	17.33%	―	78.01%	―
ALNY	66 Neutral	$40.57B	―	-414.62%	―	17.21%	21.16%
BNTX	58 Neutral	$26.60B	―	-3.87%	―	0.58%	-764.64%
Sector *	55 Neutral	€4.61B	17.01	-50.16%	3.67%	15.32%	-9.52%
SMMT	53 Neutral	$18.09B	―	-123.93%	―	―	-99.70%

Alnylam Pharma Corporate Events

Alnylam Pharma Appoints New Chief R&D Officer

On June 12, 2025, Alnylam Pharmaceuticals announced the integration of its Research and Early Development function with its Development function into a single organization, appointing Pushkal Garg as Executive Vice President, Chief Research and Development Officer. This strategic move aims to accelerate pipeline progress and foster collaboration, enhancing Alnylam’s ability to deliver RNAi therapeutics to all major tissues by 2030, thus potentially transforming patient care across a range of diseases.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Alnylam Pharma Re-elects Directors at Annual Meeting

On March 10, 2025, Alnylam Pharma held its Annual Meeting where stockholders re-elected four Class III directors to serve until 2028. Additionally, stockholders approved several key proposals, including a Certificate of Amendment, the Second Amended and Restated 2018 Stock Incentive Plan, and the compensation of named executive officers. PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALNY) stock is a Buy with a $328.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.